Ares Commercial Real Estate (ACRE) Prices 7M Share Offering at $14.96/sh

Ares Commercial Real Estate Corporation (the “Company”) (NYSE: ACRE) announced today the pricing of an underwritten public offering of 7,000,000 shares of common stock for total estimated gross proceeds of approximately $104.7 million. The Company has also granted the underwriters of the offering an option to purchase up to 1,050,000 additional shares of common stock.

The Company intends to use all of the net proceeds from the offering for general corporate purposes, including (i) investing in mortgage loans and other target assets and investments consistent with its investment strategies and investment guidelines (ii) funding commitments on existing mortgage loans and (iii) repaying indebtedness.

Morgan Stanley & Co. LLC, Wells Fargo Securities, LLC, Citigroup Global Markets Inc. and UBS Securities LLC are joint book running managers for the offering, and JMP Securities, A Citizens Company, Keefe, Bruyette & Woods, A Stifel Company, Raymond James & Associates, Inc., R. Seelaus & Co., LLC and Siebert Williams Shank & Co., LLC are co-managers for the offering.

A registration statement on Form S-3 relating to these securities has been filed with the Securities and Exchange Commission and has been declared effective. The offering may be made only by means of a prospectus supplement and accompanying prospectus. A copy of the final prospectus supplement and accompanying prospectus related to the offering can be obtained, when available, for free by visiting the Securities and Exchange Commission’s website at http://www.sec.gov or by contacting: Morgan Stanley & Co. LLC, Attention: Prospectus Department, 180 Varick Street, 2nd Floor, New York, NY 10014; Wells Fargo Securities, LLC, Attention: Equity Syndicate Department, 30 Hudson Yards, 500 West 33rd Street - 14th Floor, New York, NY 10001, by telephone at 1-800-326-5897 or by email at [email protected]; Citigroup Global Markets Inc. c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, by telephone at 1-800-831-9146 or by email at [email protected]; or UBS Securities LLC, Attention: Prospectus Department, 1285 Avenue of the Americas, New York, New York 10019, by telephone at 1-888-827-7275 or by email at [email protected].

This press release does not constitute an offer to sell or a solicitation of an offer to buy these securities, nor does it constitute an offer, solicitation or sale of these securities in any jurisdiction in which such offer, solicitation or sale is unlawful. Nothing in this press release constitutes an offer to sell or solicitation of an offer to buy any securities of the Company or an investment fund managed by the Company or its affiliates.

You May Also Be Interested In

• Rubrik IPO: 5 key things to know
• Longeveron (LGVN) Raises $11.4M in Gross Proceeds from Warrant Exercise Offering and Public Offering
• NRx Pharmaceuticals (NRXP) Prices $2M Share Offering at $3.30/sh